Mepolizumab for the treatment of chronic rhinosinusitis with nasal polyps in adults.

Josh NeposlanLeigh J SowerbyAmeen Biadsee

Published in: Expert review of respiratory medicine (2023)

: Mepolizumab is an emerging biologic therapy that shows promising potential for the treatment of CRSwNP. It appears to provide both objective and subjective improvement as an add-on therapy to standard of care treatment. Its specific role in treatment algorithms remains a topic of discussion. Future research surrounding its efficacy and cost-effectiveness as compared to alternative options is needed.

Keyphrases

chronic rhinosinusitis
rheumatoid arthritis
machine learning
palliative care
combination therapy
risk assessment
mesenchymal stem cells
replacement therapy